$AVGR
Avinger Inc Stock $avgr

$avgr Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000143774922020171 Filed on August 11, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$2.252M	$2.132M	$1.888M
YoY Change	-4.82%	-23.91%	-26.22%
Cost Of Revenue	$1.462M	$1.475M	$1.364M
YoY Change	-6.64%	-17.32%	-18.08%
Gross Profit	$790.0K	$657.0K	$524.0K
YoY Change	-1.25%	-35.46%	-41.39%
Gross Profit Margin	35.08%	30.82%	27.75%
Selling, General & Admin	$3.384M	$3.330M	$4.148M
YoY Change	-13.05%	-15.01%	5.15%
% of Gross Profit	428.35%	506.85%	791.6%
Research & Development	$1.086M	$1.086M	$1.072M
YoY Change	-22.26%	-27.94%	-32.92%
% of Gross Profit	137.47%	165.3%	204.58%
Depreciation & Amortization	$54.00K	$64.00K	$15.00K
YoY Change	-65.82%	-63.84%	-92.27%
% of Gross Profit	6.84%	9.74%	2.86%
Operating Expenses	$4.470M	$4.416M	$5.220M
YoY Change	-15.48%	-18.6%	-5.83%
Operating Profit	-$3.680M	-$3.759M	-$4.696M
YoY Change	-18.02%	-14.7%	1.01%
Interest Expense	$407.0K	$440.0K	$439.0K
YoY Change	-2.86%	10.28%	10.86%
% of Operating Profit
Other Income/Expense, Net		-$15.00K	-$5.000K
YoY Change		-100.64%	-28.57%
Pretax Income	-$4.087M	-$4.214M	-$5.140M
YoY Change	-16.8%	71.86%	1.78%
Income Tax
% Of Pretax Income
Net Earnings	-$4.087M	-$4.214M	-$5.140M
YoY Change	-16.8%	71.86%	1.74%
Net Earnings / Revenue	-181.48%	-197.65%	-272.25%
Basic Earnings Per Share	-$0.77	-$0.94	-$2.33
Diluted Earnings Per Share	-$601.2K	-$739.0K	-$1.051M
COMMON SHARES
Basic Shares Outstanding	7.040M	5.702M	4.889M
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$17.34M	$16.04M	$20.01M
YoY Change	-24.85%	-39.93%	-34.3%
Cash & Equivalents	$17.30M	$16.00M	$20.00M
Short-Term Investments
Other Short-Term Assets	$652.0K	$1.099M	$1.315M
YoY Change	-2.4%	-1.17%	-0.38%
Inventory	$5.047M	$5.178M	$5.350M
Prepaid Expenses
Receivables	$1.554M	$1.279M	$1.365M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$24.60M	$23.60M	$28.04M
YoY Change	-17.09%	-30.02%	-24.7%
LONG-TERM ASSETS
Property, Plant & Equipment	$574.0K	$520.0K	$230.0K
YoY Change	169.48%	46.48%	-58.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$333.0K	$357.0K	$406.0K
YoY Change	-26.33%	-26.54%	-14.71%
Total Long-Term Assets	$3.356M	$3.573M	$3.576M
YoY Change	-17.6%	-20.08%	-26.66%
TOTAL ASSETS
Total Short-Term Assets	$24.60M	$23.60M	$28.04M
Total Long-Term Assets	$3.356M	$3.573M	$3.576M
Total Assets	$27.95M	$27.17M	$31.61M
YoY Change	-17.15%	-28.86%	-24.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$612.0K	$727.0K	$1.172M
YoY Change	-48.05%	-29.89%	49.11%
Accrued Expenses	$669.0K	$744.0K	$816.0K
YoY Change	-15.42%	-2.62%	-4.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.072M	$6.257M	$6.007M
YoY Change	-4.93%	-3.59%	-16.97%
LONG-TERM LIABILITIES
Long-Term Debt	$13.67M	$13.19M	$12.73M
YoY Change	15.31%	15.33%	12.43%
Other Long-Term Liabilities	$881.0K	$745.0K	$719.0K
YoY Change	104.41%	159.58%	399.31%
Total Long-Term Liabilities	$881.0K	$745.0K	$719.0K
YoY Change	104.41%	159.58%	399.31%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.072M	$6.257M	$6.007M
Total Long-Term Liabilities	$881.0K	$745.0K	$719.0K
Total Liabilities	$23.01M	$21.85M	$21.38M
YoY Change	3.76%	4.5%	-1.16%
SHAREHOLDERS EQUITY
Retained Earnings	-$398.2M	-$394.1M	-$389.9M
YoY Change	4.84%	5.15%	4.7%
Common Stock	$403.1M	$399.4M	$400.1M
YoY Change	3.02%	1.86%	1.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.946M	$5.321M	$10.23M
YoY Change
Total Liabilities & Shareholders Equity	$27.95M	$27.17M	$31.61M
YoY Change	-17.15%	-28.86%	-24.93%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$4.087M	-$4.214M	-$5.140M
YoY Change	-16.8%	71.86%	1.74%
Depreciation, Depletion And Amortization	$54.00K	$64.00K	$15.00K
YoY Change	-65.82%	-63.84%	-92.27%
Cash From Operating Activities	-$3.496M	-$4.366M	-$6.181M
YoY Change	-3.48%	16.61%	28.69%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$31.00K
YoY Change		-100.0%	181.82%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00	-$31.00K
YoY Change		-100.0%	181.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.799M	399.0K	$6.721M
YoY Change		-13400.0%	-48.6%
NET CHANGE
Cash From Operating Activities	-3.496M	-4.366M	-$6.181M
Cash From Investing Activities	0.000	0.000	-$31.00K
Cash From Financing Activities	4.799M	399.0K	$6.721M
Net Change In Cash	1.303M	-3.967M	$509.0K
YoY Change	-135.97%	5.65%	-93.84%
FREE CASH FLOW
Cash From Operating Activities	-$3.496M	-$4.366M	-$6.181M
Capital Expenditures	$0.00	$0.00	$31.00K
Free Cash Flow	-$3.496M	-$4.366M	-$6.212M
YoY Change	-3.48%	16.86%	29.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	56451
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	56451
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	56451
	dei	Document Type DocumentType	10-Q
CY2021Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	56366000	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6081333
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	9000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6000	usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	56451
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	56451
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	56451
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	56451
CY2022Q2	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	56366000	usd
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6081333
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4778263
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4778263
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
CY2021Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	314000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	628000	usd
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36817
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8873453
	dei	Entity Address Address Line1 EntityAddressAddressLine1	400 Chesapeake Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94063
	dei	City Area Code CityAreaCode	650
	dei	Local Phone Number LocalPhoneNumber	241-7900
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	AVGR
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7040470
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16039000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19497000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1279000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1393000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	5178000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4601000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1099000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	300000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	23595000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	25791000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2696000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3179000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	520000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	95000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	357000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	420000	usd
CY2022Q2	us-gaap	Assets Assets	27168000	usd
CY2021Q4	us-gaap	Assets Assets	29485000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	727000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1394000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1493000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1609000	usd
CY2022Q2	us-gaap	Dividends Payable Current DividendsPayableCurrent	2255000	usd
CY2021Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	0	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	744000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	718000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1038000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	985000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	6257000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4706000	usd
CY2022Q2	us-gaap	Secured Long Term Debt SecuredLongTermDebt	13187000	usd
CY2021Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	12287000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1658000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2194000	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	745000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	575000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	21847000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	19762000	usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	96000	usd
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	399422000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	394380000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-394107000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-384753000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	5321000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	9723000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27168000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29485000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2132000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2802000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4020000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5361000	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	1475000	usd
CY2021Q2	us-gaap	Cost Of Revenue CostOfRevenue	1784000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	2839000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	3449000	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	657000	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	1018000	usd
	us-gaap	Gross Profit GrossProfit	1181000	usd
	us-gaap	Gross Profit GrossProfit	1912000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1086000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1507000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2158000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3105000	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3330000	usd
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3918000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7478000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7863000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	4416000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	5425000	usd
	us-gaap	Operating Expenses OperatingExpenses	9636000	usd
	us-gaap	Operating Expenses OperatingExpenses	10968000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3759000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4407000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8455000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9056000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	440000	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	399000	usd
	us-gaap	Interest Expense InterestExpense	879000	usd
	us-gaap	Interest Expense InterestExpense	795000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-15000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2354000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-20000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2347000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4214000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-2452000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9354000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7504000	usd
CY2022Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1127000	usd
CY2021Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1044000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2254000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2088000	usd
CY2022Q2	avgr	Preferred Stock Deemed Dividend Arising From Beneficial Conversion Feature PreferredStockDeemedDividendArisingFromBeneficialConversionFeature	-0	usd
CY2021Q2	avgr	Preferred Stock Deemed Dividend Arising From Beneficial Conversion Feature PreferredStockDeemedDividendArisingFromBeneficialConversionFeature	-0	usd
	avgr	Preferred Stock Deemed Dividend Arising From Beneficial Conversion Feature PreferredStockDeemedDividendArisingFromBeneficialConversionFeature	5111000	usd
	avgr	Preferred Stock Deemed Dividend Arising From Beneficial Conversion Feature PreferredStockDeemedDividendArisingFromBeneficialConversionFeature	-0	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5341000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3496000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16719000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9592000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.94
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.05
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5702000
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4768000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5298000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4670000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	20475000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	303000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	1044000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-2452000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	17282000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	10230000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	0	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	36000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	1127000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4214000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	5321000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	13076000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	721000	usd
	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	2088000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7504000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	17282000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	9723000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1000	usd
	avgr	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits	0	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	0	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	88000	usd
	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	2254000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9354000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	5321000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9354000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7504000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	79000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	367000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	42000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	44000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	88000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	721000	usd
	avgr	Noncash Interest Expense Income And Other Charges Net NoncashInterestExpenseIncomeAndOtherChargesNet	858000	usd
	avgr	Noncash Interest Expense Income And Other Charges Net NoncashInterestExpenseIncomeAndOtherChargesNet	753000	usd
	avgr	Change In Rightofuse Asset ChangeInRightofuseAsset	48000	usd
	avgr	Change In Rightofuse Asset ChangeInRightofuseAsset	68000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	86000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	22000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-10000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	2353000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-111000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	314000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1134000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	241000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	799000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	762000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-15000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	44000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-668000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	343000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-116000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-36000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	26000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	95000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	170000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	287000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10547000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8544000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-31000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-18000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7120000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13077000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3458000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4515000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	19497000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22185000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16039000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	26700000	usd
	avgr	Accretion Of Preferred Stock Dividends AccretionOfPreferredStockDividends	2254000	usd
	avgr	Accretion Of Preferred Stock Dividends AccretionOfPreferredStockDividends	2088000	usd
	avgr	Reclassification Of Right Of Use Asset To Prepaid Rent ReclassificationOfRightOfUseAssetToPrepaidRent	-48000	usd
	avgr	Reclassification Of Right Of Use Asset To Prepaid Rent ReclassificationOfRightOfUseAssetToPrepaidRent	-68000	usd
	avgr	Transfers Between Inventory And Property And Equipment TransfersBetweenInventoryAndPropertyAndEquipment	471000	usd
	avgr	Transfers Between Inventory And Property And Equipment TransfersBetweenInventoryAndPropertyAndEquipment	-23000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;">1.</em> Organization</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Organization, Nature of Business</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Avinger, Inc. (the “Company”), a Delaware corporation, was incorporated in <em style="font: inherit;"> March </em><em style="font: inherit;">2007.</em> The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (“PAD”). Patients with PAD have a build-up of plaque in the arteries that supply blood to areas away from the heart, particularly the pelvis and legs. The Company manufactures and sells a suite of products in the United States (“U.S.”) and in select international markets. The Company has developed its Lumivascular platform, which integrates optical coherence tomography (<em style="font: inherit;"> “OCT”) </em>visualization with interventional catheters and is the industry’s only system that provides real-time intravascular imaging during the treatment portion of PAD procedures. The Company’s Lumivascular platform consists of a capital component, our Lightbox consoles, as well as a variety of disposable catheter products. The Company’s current catheter products include Ocelot and Tigereye, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (“CTO”). The Company also has image-guided atherectomy products, Pantheris and Pantheris SV, which are designed to allow physicians to precisely remove arterial plaque in PAD patients. The Company is in the process of developing next-generation CTO crossing devices to target coronary CTO markets. The Company is located in Redwood City, California.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Liquidity Matters</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception. As of <em style="font: inherit;"> June 30, 2022, </em>the Company had an accumulated deficit of $394.1 million. The Company expects to incur losses for the foreseeable future. The Company believes that its cash and cash equivalents of $16.0 million at <em style="font: inherit;"> June 30, 2022 </em>and expected revenues and funds from operations will be sufficient to allow the Company to fund its current operations through the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2023.</em> The Company received net proceeds of approximately $6.7 million from the <em style="font: inherit;"> January 2022 </em>Series D preferred stock equity financing and $13.0 million from the sale of its common stock in <em style="font: inherit;"> February 2021. </em>The Company <em style="font: inherit;"> may </em>seek to raise additional funds in future equity offerings to meet its operational needs and capital requirements for product development, clinical trials and commercialization or other strategic objectives.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company can provide <em style="font: inherit;">no</em> assurance that it will be successful in raising funds pursuant to additional equity or debt financings or that such funds will be raised at prices that do <em style="font: inherit;">not</em> create substantial dilution for its existing stockholders. Given the volatility in the Company’s stock price, any financing that the Company <em style="font: inherit;"> may </em>undertake in the next <em style="font: inherit;">twelve</em> months could cause substantial dilution to its existing stockholders, and there can be <em style="font: inherit;">no</em> assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its various endeavors. In addition, the COVID-<em style="font: inherit;">19</em> pandemic and responses thereto have resulted in reduced consumer and investor confidence, instability in the credit and financial markets, volatile corporate profits, restrictions on elective medical procedures, and reduced business and consumer spending, which could increase the cost of capital and/or limit the availability of capital to the Company.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable to it, the Company <em style="font: inherit;"> may </em>have to significantly reduce its operations or delay, scale back or discontinue the development and sale of <em style="font: inherit;">one</em> or more of its products. The financial statements do <em style="font: inherit;">not</em> include any adjustments that might result from the outcome of this uncertainty. The Company’s ultimate success will largely depend on its continued development of innovative medical technologies, its ability to successfully commercialize its products and its ability to raise significant additional funding.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Public Offerings</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Past Offerings</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> February 2, 2021, </em>under the shelf registration statement, the Company completed a bought deal offering of 500,000 shares of common stock at an offering price of $28.80 per share. As a result, the Company received aggregate net proceeds of approximately $13.0 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i><em style="font: inherit;"> January 2022 </em>Offering</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> January 14, 2022, </em>the Company entered into a securities purchase agreement with several institutional investors pursuant to which the Company agreed to sell and issue, in a registered direct offering (<em style="font: inherit;"> “January 2022 </em>Offering”), an aggregate of 7,600 shares of the Company’s Series D Convertible Preferred Stock, par value of $0.001 per share, at an offering price of $1,000 per share which was convertible into common stock at a conversion price of $8.00 per share. Concurrently, the Company agreed to issue to these investors warrants to purchase up to an aggregate of 807,500 shares of the Company’s common stock (the “Common Warrants”). As a result, the Company received aggregate net proceeds of approximately $6.7 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The 807,500 Common Warrants have an exercise price of $9.60 per share and became exercisable beginning <em style="font: inherit;"> July 14, 2022. </em>The Common Warrants will expire <span style="-sec-ix-hidden:c86419130">five</span> years following the time they become exercisable, or <em style="font: inherit;"> July 14, 2027. </em>The Company also issued to the Placement Agent or its designees warrants to purchase up to an aggregate of 66,500 shares of common stock (the “Placement Agent Warrants”). The Placement Agent Warrants are subject to the same terms as the Common Warrants, except that the Placement Agent Warrants have an exercise price of $10.00 per share and a term of <span style="-sec-ix-hidden:c86419133">five</span> years from the commencement of the sales pursuant to the <em style="font: inherit;"> January 2022 </em>Offering, or <em style="font: inherit;"> January 12, 2027.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>At the Market Offering Agreement</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> May 20, 2022, </em>the Company entered into an At the Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (the “Agent”), as sales agent, pursuant to which the Company <em style="font: inherit;"> may </em>offer and sell shares of common stock, par value $0.001 per share (the “Shares”) up to an aggregate offering price of $7,000,000 from time to time, in an at-the-market public offering. Sales of the Shares are to be made at prevailing market prices at the time of sale, or as otherwise agreed with the Agent. The Agent will receive a commission from the Company of 3.0% of the gross proceeds of any Shares sold under the ATM Agreement. The Shares sold under the ATM Agreement are offered and sold pursuant to the Company’s shelf registration statement on Form S-<em style="font: inherit;">3,</em> which was initially filed with the Securities and Exchange Commission (the “SEC”) on <em style="font: inherit;"> March 29, 2022 </em>and declared effective on <em style="font: inherit;"> April 7, 2022, </em>and a prospectus supplement and the accompanying prospectus relating to the at-the-market offering filed with the SEC on <em style="font: inherit;"> May 20, 2022. </em>During the quarter ended <em style="font: inherit;"> June 30, 2022, </em>the Company sold 326,466 shares of common stock pursuant to the ATM Agreement at an average price of $1.76 per share for aggregate proceeds of approximately $0.6 million, of which approximately $17,000 was paid in the form of commissions to the Agent. Other than the ATM Agreement, the Company currently does <em style="font: inherit;">not</em> have any commitments to obtain additional funds. Subsequent to <em style="font: inherit;"> June 30, 2022, </em>the Company sold an additional 259,137 shares of common stock at an average price of $1.56 per share for aggregate net proceeds of $0.4 million, of which approximately $12,000 was paid in the form of commissions to the Agent. On <em style="font: inherit;"> August 3, 2022, </em>the Company suspended sales under the ATM Agreement. While the Company <em style="font: inherit;"> may </em>resume sales in the future, there can be <em style="font: inherit;">no</em> assurance that the Company will be successful in acquiring additional funding through these means.</p>
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-394100000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16000000.0	usd
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	326466
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Use of Estimates</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its stock-based compensation, accruals related to compensation, the valuation of the common stock warrants, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and its reserves for sales returns and warranty costs. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <em style="font: inherit;">not</em> readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it <em style="font: inherit;"> may </em>undertake in the future, actual results <em style="font: inherit;"> may </em>ultimately materially differ from these estimates and assumptions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2022Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	171000	usd
CY2021Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	211000	usd
CY2021Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	187000	usd
CY2020Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	193000	usd
CY2022Q2	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	0	usd
CY2021Q2	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	21000	usd
	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	4000	usd
	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	41000	usd
CY2022Q2	avgr	Product Warranty Accrual Payments And Release ProductWarrantyAccrualPaymentsAndRelease	34000	usd
CY2021Q2	avgr	Product Warranty Accrual Payments And Release ProductWarrantyAccrualPaymentsAndRelease	1000	usd
	avgr	Product Warranty Accrual Payments And Release ProductWarrantyAccrualPaymentsAndRelease	54000	usd
	avgr	Product Warranty Accrual Payments And Release ProductWarrantyAccrualPaymentsAndRelease	3000	usd
CY2022Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	137000	usd
CY2021Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	231000	usd
CY2022Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	137000	usd
CY2021Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	231000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5341000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3496000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16719000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9592000	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5702000
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4768000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5298000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4670000
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.94
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.05
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1072960
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	207675
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2696000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3179000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1008832
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	207627
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	314000	usd
CY2022Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3156000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2503000	usd
CY2022Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	338000	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1000	usd
CY2022Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1684000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2097000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	5178000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4601000	usd
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5800000	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y4M24D
CY2021Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.065	pure
	avgr	Operating Lease Expense Excluding Maintenance Fee And Other Expense Monthly OperatingLeaseExpenseExcludingMaintenanceFeeAndOtherExpenseMonthly	105000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3179000	usd
	us-gaap	Preferred Stock Redemption Discount PreferredStockRedemptionDiscount	5111000	usd
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6081333
	us-gaap	Operating Lease Expense OperatingLeaseExpense	628000	usd
CY2022Q2	us-gaap	Variable Lease Cost VariableLeaseCost	71000	usd
CY2021Q2	us-gaap	Variable Lease Cost VariableLeaseCost	59000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	137000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	118000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	265000	usd
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	253000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	531000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	502000	usd
CY2022Q2	us-gaap	Prepaid Rent PrepaidRent	110000	usd
CY2021Q4	us-gaap	Prepaid Rent PrepaidRent	158000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	583000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1203000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1138000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2924000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	228000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	2696000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2696000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1038000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	985000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1658000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2194000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	2696000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3179000	usd
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	56451
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	26456895
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	132265
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	43936895
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1006285
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1006285
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	132265
CY2022Q2	us-gaap	Share Price SharePrice	1.46
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	36000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	303000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	88000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	721000	usd

Files In Submission

Name	View Source	Status
0001437749-22-020171-index-headers.html	Edgar Link	pending
0001437749-22-020171-index.html	Edgar Link	pending
0001437749-22-020171.txt	Edgar Link	pending
0001437749-22-020171-xbrl.zip	Edgar Link	pending
avgr-20220630.xsd	Edgar Link	pending
avgr20220630_10q.htm	Edgar Link	pending
ex_407417.htm	Edgar Link	pending
ex_407651.htm	Edgar Link	pending
ex_407652.htm	Edgar Link	pending
ex_410058.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
avgr-20220630_cal.xml	Edgar Link	unprocessable
avgr-20220630_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
avgr-20220630_pre.xml	Edgar Link	unprocessable
avgr-20220630_lab.xml	Edgar Link	unprocessable
avgr20220630_10q_htm.xml	Edgar Link	completed
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVGR
Avinger Inc Stock $avgr

2022 Q3 Form 10-Q Financial Statement

#000143774922020171 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVGR Avinger Inc Stock $avgr

2022 Q3 Form 10-Q Financial Statement

#000143774922020171 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVGR
Avinger Inc Stock $avgr